Semaglutide's real-world effectiveness in Type 2 Diabetes investigated in French observational study

Type 2 Diabetes (T2D) is a chronic metabolic condition characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose. While randomized controlled trials (RCTs) establish efficacy and safety under ideal conditions, real-world evidence (RWE) is crucial for understanding how treatments perform in diverse patient populations with comorbidities and varying adherence in routine clinical practice. This study aims to bridge that gap for semaglutide, a widely used GLP-1R agonist, by observing its effectiveness and patient experience in a naturalistic setting within France.

The SURE FRANCE study is a prospective, non-interventional, real-world observational study designed to collect data on semaglutide use in routine clinical practice. Participants, diagnosed with Type 2 Diabetes, will receive semaglutide as prescribed by their study doctor, reflecting standard local clinical care. The study duration is approximately 6 to 8 months. Throughout this period, participants will complete questionnaires about their health and diabetes treatment during their regularly scheduled clinic visits, allowing for the collection of patient-reported outcomes and treatment effectiveness data.

The provided abstract describes the study's purpose and design but does not present any findings or results. This is an ongoing or recently completed observational study, and its outcomes regarding semaglutide effectiveness, patient-reported health, or changes in diabetes treatment are not yet available in this record. Therefore, no specific numerical results, p-values, or fold-changes can be reported at this time.